151 related articles for article (PubMed ID: 17199217)
1. New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease.
Ruilope LM
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S29-31. PubMed ID: 17199217
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
5. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
[TBL] [Abstract][Full Text] [Related]
6. Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
Cohn JN
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S38-40. PubMed ID: 17199220
[TBL] [Abstract][Full Text] [Related]
7. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Estacio RO; Coll JR; Tran ZV; Schrier RW
Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
[TBL] [Abstract][Full Text] [Related]
8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
9. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
[TBL] [Abstract][Full Text] [Related]
11. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
13. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
[TBL] [Abstract][Full Text] [Related]
14. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
15. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Ferri C; Croce G; Desideri G
Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Yoneda T; Takeda Y; Usukura M; Oda N; Takata H; Yamamoto Y; Karashima S; Yamagishi M
Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
[TBL] [Abstract][Full Text] [Related]
17. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
[TBL] [Abstract][Full Text] [Related]
18. Reduction of proteinuria with angiotensin receptor blockers.
Galle J
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
20. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
Ferrari P
Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
